Pinterest Inc vs BIO-TECHNE Corp — how do they compare? Pinterest Inc trades at $18.35 (market cap $11.41B), while BIO-TECHNE Corp trades at $72.39 (market cap $11.34B). The key difference: Pinterest Inc and BIO-TECHNE Corp are close in size by market cap, and BIO-TECHNE Corp pays a 0.44% dividend while Pinterest Inc pays none. Which is the better fit depends on your goals.
| PINS | TECH | |
|---|---|---|
Market Cap | $11.41B | $11.34B |
Sector | Media | Health |
52-Week High | $36.49 | $72.48 |
52-Week Low | $15.42 | $43.31 |
Enterprise Value | $11.33B | $11.36B |
Dividend Yield | — | 0.44% |
Signals from Pluang's Aura AI — not financial advice
Pinterest (PINS) trades at $20.14, down 1.27% with bearish technical signals despite recent earnings beats. The company shows strong revenue growth from $2.8B in 2022 to $4.2B in 2025, though net income margin compressed to 5.46%. Recent CFO resignation and insider selling have weighed on sentiment, while analyst consensus remains bullish with a $28.69 price target representing 42% upside potential.
PINS offers significant upside based on analyst targets but faces near-term headwinds from leadership transition and competitive pressures. The stock's high P/E ratio of 59.24 requires continued execution on AI-driven growth initiatives. Key risks include market share competition and the company's ability to monetize international users effectively while managing rising infrastructure costs from the $4B AWS partnership.
Bio-Techne (TECH) trades at $72.31, down 0.17% on the day, with a neutral technical signal and mixed earnings history. The stock is near the consensus price target of $71.86, with a pending acquisition by Merck KGaA at $73.00 per share. Recent Q4 2026 revenue beat estimates, but net income margin compression from 25.09% in 2023 to 14.96% in 2026 highlights profitability challenges. Operating cash flow remains stable around $290M, supporting dividend payments.
The outlook is balanced, with upside capped by the acquisition offer but supported by solid cash flow and analyst hold ratings. Risks include shareholder litigation and integration uncertainties post-acquisition. Earnings growth in diagnostics and spatial biology segments is a key catalyst, though high P/E of 62.33 suggests elevated expectations.
Trailing returns across standard periods
Latest headlines on both assets
Pinterest is an online product and idea discovery platform that helps users gather ideas on everything from recipes to cook to destinations to travel to. Founded in 2010, the platform consists of a largely female audience, at roughly two thirds of its more than 365 million monthly active users. The company generates revenue by selling digital ads and is now rolling out more in-platform e-commerce features.
Read more on PINS →Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →